Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.158
Sell
RSI(14)
28.378
Sell
STOCH(KDJ)(9,3,3)
2.593
Oversold
ATR(14)
0.272
Low Volatility
CCI(14)
-98.431
Neutral
Williams %R
98.906
Oversold
TRIX(12,20)
-1.561
Sell
StochRSI(14)
0.000
Oversold
Onconetix Inc
ONCO1.520USD
-0.060-3.80%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.37MMarket Cap
0.00P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Onconetix Inc
Currency: USD Updated: 2025-12-24Key Insights
Onconetix Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 123/158 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Onconetix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Onconetix Inc Highlights
StrengthsRisks
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.52M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.52M.
Overvalued
The company’s latest PE is 0.00, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 22.38K shares, increasing 43.25% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Onconetix Inc is 5.49, ranking 156/158 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 303.65K, representing a year-over-year decrease of 25.37%, while its net profit experienced a year-over-year decrease of 129.49%.
Score
Financials
4.56
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.85
Operational Efficiency
2.83
Growth Potential
6.12
Shareholder Returns
7.07
Onconetix Inc's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Onconetix Inc is 7.52, ranking 66/158 in the Pharmaceuticals industry. Its current P/E ratio is 0.00, which is 100.00% below the recent high of 0.00 and 4721233.33% above the recent low of -56.65.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 123/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24No earnings forecast score is currently available for Onconetix Inc. The Pharmaceuticals industry's average is 7.80.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Onconetix Inc is 5.31, ranking 144/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 2.66 and the support level at 0.94, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.663
Sell
MA10
1.874
Sell
MA20
2.297
Sell
MA50
2.712
Sell
MA100
2.894
Sell
MA200
4.457
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-24The current institutional shareholding score of Onconetix Inc is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 5.65%, representing a quarter-over-quarter decrease of 85.39%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Onconetix Inc is 2.04, ranking 136/158 in the Pharmaceuticals industry. The company's beta value is 3.44. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
3.44
VaR
--
240-Day Maximum Drawdown
+97.31%
240-Day Volatility
+190.00%
Return
Best Daily Return
60 days
+19.31%
120 days
+19.31%
5 years
--
Worst Daily Return
60 days
-17.50%
120 days
-22.52%
5 years
--
Sharpe Ratio
60 days
-2.21
120 days
-1.60
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+97.31%
3 years
+99.97%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.99
3 years
-0.33
5 years
--
Skewness
240 days
+0.38
3 years
+4.57
5 years
--
Volatility
Realised Volatility
240 days
+190.00%
5 years
--
Standardised True Range
240 days
+108.28%
5 years
--
Downside Risk-Adjusted Return
120 days
-250.97%
240 days
-250.97%
Maximum Daily Upside Volatility
60 days
+81.82%
Maximum Daily Downside Volatility
60 days
+71.71%
Liquidity
Average Turnover Rate
60 days
+25.85%
120 days
+139.32%
5 years
--
Turnover Deviation
20 days
-99.83%
60 days
-95.55%
120 days
-76.03%
Peer Comparison
Pharmaceuticals
Onconetix Inc
ONCO
4.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Onconetix Inc?
The TradingKey Stock Score provides a comprehensive assessment of Onconetix Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Onconetix Inc’s performance and outlook.
How do we generate the financial health score of Onconetix Inc?
To generate the financial health score of Onconetix Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Onconetix Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Onconetix Inc.
How do we generate the company valuation score of Onconetix Inc?
To generate the company valuation score of Onconetix Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Onconetix Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Onconetix Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Onconetix Inc.
How do we generate the earnings forecast score of Onconetix Inc?
To calculate the earnings forecast score of Onconetix Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Onconetix Inc’s future.
How do we generate the price momentum score of Onconetix Inc?
When generating the price momentum score for Onconetix Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Onconetix Inc’s prices. A higher score indicates a more stable short-term price trend for Onconetix Inc.
How do we generate the institutional confidence score of Onconetix Inc?
To generate the institutional confidence score of Onconetix Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Onconetix Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Onconetix Inc.
How do we generate the risk management score of Onconetix Inc?
To assess the risk management score of Onconetix Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Onconetix Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Onconetix Inc.
